Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria

NCT00425607 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Progeria
Hutchinson-Gilford Syndrome

Interventions

DRUG: Lonafarnib

Sponsor

Monica E. Kleinman

Collaborators

[object Object]